Argentina, Theratechnoligies files for authorization to sell tesamorelin for HIV patients

Posted on September 1, 2011 • Filed under: Argentina, Latin America Health

Theratechnologies Inc. CA:TH -1.03% THER -2.27% today announced that an affiliate of Sanofi, its commercial partner, has filed a marketing authorization application for tesamorelin in Argentina with the Ministry of Health’s National Administration of Drugs, Foods and Medical Technology (ANMAT).

Tesamorelin is proposed for the treatment of excess abdominal fat in HIV-infected patients with lipodystrophy. Theratechnologies estimates that there are approximately 13,000 HIV-infected patients suffering from excess abdominal fat in Argentina. Currently, there are no approved treatments available for this condition in South America. Read Article

Share This Story
  • Print
  • Digg
  • StumbleUpon
  • Facebook
  • Yahoo! Buzz
  • Twitter
  • Google Bookmarks
  • Add to favorites
  • email